Hidradenitis suppurativa treated with<i>Clostridium botulinum</i>toxin A

Khoo, Andre Boo Shern; Burova,

doi:10.1111/ced.12380

Cited by 33 publications

(33 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Khoo has demonstrated the effectiveness of subsequent treatments in the same patient. The patient, suffering from HS and hyperhidrosis involving axillae and groin, was treated four times over the course of 3 years until a complete remission of HS (Khoo & Burova, ). It is not clear how botulinum toxin a can improve HS, also because this disease only rarely is accompanied by hyperhidrosis, for which is largely known that botulinum toxin is an effective and safe treatment (Campanati et al, ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage

Campanati

Martina

Giuliodori

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Hidradenitis suppurativa is a chronic skin disease with an intense inflammatory activation. It typically affects the intertriginous areas with cysts, fistulae, and scarring extremely painful. Patients suffer from severe psychological impact. HS still results in a high unmet medical need with several underdiagnosed cases, probably due to the incomplete knowledge of the pathogenesis of HS. The use of botulinum toxin a has recently been proposed as an effective therapy for HS.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The first treatment of HS with botulinum toxin a was described in (Khoo & Burova, 2014). It is not clear how botulinum toxin a can improve HS, also because this disease only rarely is accompanied by hyperhidrosis, for which is largely known that botulinum toxin is an effective and safe treatment (Campanati et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage

Campanati

Martina

Giuliodori

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…The reoccurrence responded to a similar second treatment. Khoo and Burova confirmed the efficacy of BoNT treatment in HS in 3 cases [53] . One of them, a 46-year-old woman, was affected by a Hurley stage II HS and hyperhidrosis involving axillae and groin, recalcitrant to conventional therapies and also previously treated with surgical drainage of abscesses.…”

Section: Hidradenitis Suppurativamentioning

confidence: 77%

Botulinum Toxin Off-Label Use in Dermatology: A Review

Campanati

Martina

Giuliodori

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

focal hyperhidrosis, aesthetic medicine and neurological conditions with a strong efficacy and safety profile [1][2][3][4][5][6][7] . The enormous therapeutic potential of this drug contributed to a number of broad applications, especially in dermatological diseases. A large number of these indications are still lacking shared, approved protocols for dilution, doses, and timing of follow-up and retreatment. Also the injection techniques are still debated, depending on the operator's experience, angle of injection and depth. We have previously published a novel injection approach consisting in a needle adaptor that ensures a uniform administration of the toxin [3] . The aim of this review was to collect and analyze the published data concerning the most relevant off-label indications of BoNT-A. MethodsA PubMed search from 1950 to July 2016 was performed to identify any reports on the use of botulinum toxin in off-label indications concerning dermatology. We detected these articles using the terms "botulinum toxin dermatology," "botulinum toxin treatment," "botulinum toxin off-label," and meshed with a secondary search of studies pertaining to each indication. Only studies in English were reviewed. All studies that met the criteria were included and summarized in this review. KeywordsBotulinum toxin · Off-label therapy · Keloids · Hidradenitis suppurativa · Folds dermatitis Abstract Background: Botulinum toxin is a neurotoxin produced by the bacterium Clostridium botulinum which causes a flaccid muscle paralysis. It is currently used for aesthetic treatments and in the focal hyperhidrosis. Recently, botulinum toxin has also been used experimentally in many other dermatological conditions with good results. Objective: To review and analyze the possible botulinum toxin off-label applications published. Methods: A retrospective review of the published data was conducted. Conclusions: this potent drug can lead to several off-label indications of interest for dermatologists. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and dose protocols.

show abstract

“…81,82 In addition, topical retinoids, azelaic acid or fusidic acid also have been used in limited cases.…”

Section: -Topical Therapymentioning

confidence: 99%

Update on Hidradenitis Suppurativa (Part I): Epidemiology, Pathogenesis, Severity assessment and Comorbidities

Silva

Azevedo

Lisboa

2018

SPDV

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is as a chronic, inflammatory and recurrent skin disease of the hair follicle. Prevalence of HS is a matter of debate, with estimate rates as low as 0.00033% and as high as 4.1%. HS prevalence appears significantly higher in women and has a mean age of onset in the early 20s. The primary histopathologic event seems to be a follicular hyperkeratosis with plugging, dilatation and rupture of the hair follicle resulting with subsequent inflammation and formation of abscesses and sinus tracts. The cause of this is likely multifactorial, involving genetic factors, cigarette smoking, mechanical stress, obesity, immune aberrant response and hormonal abnormalities. HS, as a chronic inflammatory dermatosis, is associated with a variety of concomitant and secondary diseases such as metabolic syndrome, inflammatory and rheumatologic diseases, depression and malignancy, and, for this reason HS management often requires a multidisciplinary team.

show abstract

Hidradenitis suppurativa treated withClostridium botulinumtoxin A

Cited by 33 publications

References 4 publications

Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage

Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage

Botulinum Toxin Off-Label Use in Dermatology: A Review

Update on Hidradenitis Suppurativa (Part I): Epidemiology, Pathogenesis, Severity assessment and Comorbidities

Contact Info

Product

Resources

About